Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes

NCT07117240 · Enrolling by invitation

Last updated 2026-05-28

This clinical trial is testing a GLP-1 receptor agonist medication in adults who develop diabetes or high blood sugar due to steroid treatment.

Status Enrolling by invitation Only people invited by the researchers can join.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) prevention study

Participants 100 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-07 · est. completion 2028-07

Where 1 site · Poland

What this study is testing ClinicalTrials.gov NCT07117240 ↗

Description as written by the study sponsor.

Glucocorticoids are commonly used in the treatment of autoimmune, inflammatory, and neoplastic diseases. Despite their therapeutic efficacy, they are associated with significant metabolic side effects. In the proposed research, the aim is to assess the metabolic efficacy and safety of fixed-ratio combination therapy (basal insulin + GLP-1 receptor agonist) compared to standard insulin therapy in patients with SID. In a selected group of patients, a randomised clinical trial would be conducted to assess the potential benefits of GLP-1 receptor agonists in the management of SID.

Treatments tested

lixisenatide + glargine also known as GLP-1 plus basal insulin Drug

Participants assigned to Group 1 will receive standard insulin therapy. Those in Group 2 will be treated with a combination of insulin glargine and lixisenatide, with dosages individually adjusted based on current glucose levels. All participants will be trained in insulin administration and dose adjustment based on glucose readings.
Intensive insulin therapy Drug

Participants assigned to Group 1 will receive standard insulin therapy. Those in Group 2 will be treated with a combination of insulin glargine and lixisenatide, with dosages individually adjusted based on current glucose levels. All participants will be trained in insulin administration and dose adjustment based on glucose readings.

Main thing measured	Glucose monitoring index and Time in range
Sponsor	Medical University of Warsaw
Conditions studied	Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia, Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07117240 ↗